moneyheap
VCYT · Analysis updated Nov 6, 2026, 9:55 AM ET
Why is Veracyte, Inc. (VCYT) stock moving?
Veracyte fell about 54-56% on Nov 5, from $52.52 to roughly $24, on volume near 15M shares, about 10 times the recent daily average. The quarter itself was solid: revenue rose 15% to $151.8M, adjusted EPS of $0.51 beat the $0.41 estimate, adjusted EBITDA was $41.2M, and GAAP net income was $31.5M. The selloff came from a second straight Decipher Prostate volume miss of about 1,000 tests, a narrowed 2026 revenue guide of $590-593M, and a preliminary 2027 outlook of only mid-single-digit growth. That ended the double-digit growth story the stock had been priced for after a run from about $44 to $52 in late October. Leerink downgraded the stock to Market Perform with a $35 target, and Needham cut its target to $46 but kept a Buy. William Blair kept its Outperform rating. Supports include a $100M buyback, $370.5M in cash, strong Afirma growth, and sustained profitability. Risks include the growth-multiple reset, analyst target cuts, heavy insider selling over the past year, and likely continued volatility and forced selling after a crash this size.
News behind the analysis
- Veracyte stock downgraded at Leerink on guidance cutShares fell more than 50% after the company lowered its full-year outlook with Q3 results. Leerink Partners downgraded the stock.
- Veracyte (VCYT) Shares Plunge Over 50% After Revenue Guidance Cut in Q3 2026 Report2026 revenue guidance was cut to $590M-$593M, slightly below the $593.8M consensus. Insider selling totaled $22.6M over the past 12 months.
- Veracyte plunges 56% after updated 2026 revenue outlookThe stock fell $29.18 to $23.34 in the final half hour of trading after the Q3 report and outlook update.
- Veracyte (VCYT) Shares Drop 56% After Q3 Earnings and Lowered 2026 Revenue GuidanceThe stock hit a 52-week low of $21.93 on volume well above average.
- Why is Veracyte stock plummeting today?Q3 revenue rose 15% to $151.8M and adjusted EPS of $0.51 beat the $0.41 consensus. The 2027 outlook calls for only mid-single-digit growth. Leerink cut its rating to Market Perform with a $35 target, and Needham cut its target from $69 to $46.
- Why Is Veracyte Stock Sinking Thursday?Decipher Prostate volume came in about 1,000 tests below internal expectations, the second straight shortfall. William Blair kept its Outperform rating. A $100M buyback was also announced.
- Veracyte stock hits 52-week low at 28.81 USDManagement cut 2026 revenue guidance on lower expected Decipher volume growth but kept its EBITDA margin guidance. Needham kept its Buy rating.
- Veracyte Announces Third Quarter 2026 Financial ResultsTotal revenue was $151.8M, up 15%. Adjusted EBITDA was $41.2M, or 27.2% of revenue. Product revenue rose 40% to $4.6M.
- Veracyte Reports Strong Third-Quarter Results and Revenue GrowthGAAP net income was $31.5M and operating cash flow was $40.3M. Cash and short-term investments were $370.5M. The company also acquired Convergent Genomics and announced a $100M, 12-month buyback.
- Veracyte (VCYT) Q3 2026 Earnings Call TranscriptAfirma volume rose 12% to 19,100 tests. Decipher Prostate volume was about 30K tests, up 12%, and about 1K below plan. Q4 volume is expected to be roughly flat sequentially.